首页> 外文OA文献 >PCN88 Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.: a cost-effectiveness analysis

【2h】

PCN88 Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.: a cost-effectiveness analysis

机译：PCN88比较酪氨酸激酶抑制剂在伊马替尼失去美国专利权后在慢性期新诊断的慢性粒细胞白血病的治疗策略：成本效益分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Padula W.; Larson R.; Conti R.; Dusetzina S.;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70. [J] . Doggrell SA, Christensen AM Expert opinion on pharmacotherapy . 2011,第1期

机译：是否有比伊马替尼更好的Bcr-Abl激酶抑制剂用于慢性粒细胞白血病？ Saglio G，Kim D-W，Issaragrisil S等的评估。尼洛替尼与伊马替尼治疗新诊断的慢性粒细胞白血病。 N Engl J Med 2010; 362：2251-9，and Kantarjian H，Shah NP，Hochhaus A等。达沙替尼与伊马替尼治疗新近诊断的慢性期慢性粒细胞白血病。 N Engl J Med 2010; 362：2260-70。
2. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States [J] . Padula William V., Larson Richard A., Dusetzina Stacie B., Journal of the National Cancer Institute . 2016,第7期

机译：酪氨酸激酶抑制剂治疗策略在美国伊马替尼的通用进入后慢性期慢性粒细胞白血病的成本效益。
3. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. [J] . Cortes JE, Baccarani M, Guilhot Journal of Clinical Oncology . 2010,第3期

机译：使用分子终点研究：酪氨酸激酶抑制剂优化和选择性研究，在新诊断，先前未治疗的慢性粒细胞白血病的慢性期患者中，每天进行400毫克甲磺酸伊马替尼与800毫克甲磺酸伊马替尼的随机，开放标签研究。
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States [O] . William V. Padula, Richard A. Larson, Stacie B. Dusetzina, -1

机译：酪氨酸激酶抑制剂治疗策略在美国伊马替尼的通用进入后慢性期慢性粒细胞白血病的成本效益。
7. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States [O] . Padula WV, Larson RA, Dusetzina SB, 2016

机译：美国伊马替尼一般入境后慢性髓性白血病酪氨酸激酶抑制剂治疗策略的成本效益

PCN88 Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.: a cost-effectiveness analysis

著录项

相似文献

相关主题

期刊订阅